CPRX logo

CPRX
Catalyst Pharmaceuticals Inc

15,764
Mkt Cap
$3.81B
Volume
4.13M
52W High
$32.56
52W Low
$19.05
PE Ratio
17.91
CPRX Fundamentals
Price
$31.16
Prev Close
$31.16
Open
$31.17
50D MA
$26.05
Beta
0.97
Avg. Volume
1.9M
EPS (Annual)
$1.68
P/B
3.76
Rev/Employee
$3.24M
$2,263.82
Loading...
Loading...
News
all
press releases
CPRX or UTHR: Which Is the Better Value Stock Right Now?
CPRX vs. UTHR: Which Stock Is the Better Value Option?
Zacks·8h ago
News Placeholder
More News
News Placeholder
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX beats Q1 estimates driven by rising Firdapse and Agamree sales amid Angelini Pharma's pending $4.1B acquisition deal.
Zacks·2d ago
News Placeholder
Are CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders?
Are CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders? Are CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 12, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...
PR Newswire·3d ago
News Placeholder
Catalyst (CPRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·3d ago
News Placeholder
Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings and Revenue Estimates
Catalyst (CPRX) delivered earnings and revenue surprises of +23.44% and +1.57%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX...
Business Wire·5d ago
News Placeholder
Are CPRX, TBRG, MDV, ACR Obtaining Fair Deals for their Shareholders?
Are CPRX, TBRG, MDV, ACR Obtaining Fair Deals for their Shareholders? Are CPRX, TBRG, MDV, ACR Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 8, 2026 Insiders may stand to...
PR Newswire·6d ago
News Placeholder
Perrigo Q1 Earnings Surpass Estimates, Sales Miss, Both Fall Y/Y
PRGO beats Q1 EPS estimates despite lower sales. Weakness in cough and cold demand offsets gains in Women's Health and Infant Formula.
Zacks·7d ago
News Placeholder
UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook
United Therapeutics shares rise after Q1 earnings miss estimates as investors focus on Tyvaso IPF data and ralinepag's blockbuster potential.
Zacks·7d ago
News Placeholder
Family-Run Angelini Pharma Buys Catalyst Pharmaceuticals For Over 4 Billion
Catalyst Pharmaceuticals stock rose after Angelini Pharma agreed to acquire the rare disease drugmaker in a $4.1 billion cash deal.read more...
Benzinga·7d ago
<
1
2
...
>

Latest CPRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.